2025-06-09-花旗集团-阿维迪蒂生物科学公司（RNA）_阿维迪蒂生物科学公司（RNA.O）_在面肩肱型肌营养不良症（FSHD）中来自del_-_brax的鼓舞性数据支持加速审批_10页_220kb

Summary of Citi Research Report on Avidity Biosciences Inc

• Company Overview: Avidity Biosciences Inc (RNA.O) focuses on rare disease treatments using its antibody oligonucleotide conjugate (AOC) platform. The report highlights updates from the del-brax program in Facioscapulophrangulopathy (FSHD), a rare condition.

• Key Updates and Developments: Del-brax received positive topline phase 1/2 data (FORTITUDE) for FSHD, supporting an accelerated FDA approval pathway. A global phase 3 trial (FORWARD) is underway with ~200 patients, aiming to confirm full approval through functional endpoints. A BLA filing is expected in H2 2026, contingent on 2026 biomarker data.

• Valuation: Citigroup sets a target price of $70 based on a DCF model using a 12.5% WACC and 2% terminal growth rate. Expected total return is 93.2%, with a market capitalization of $4.368 billion.

• Analyst Recommendation: Maintain "Buy" rating with a high-risk tag, emphasizing the AOC platform's potential but cautioning on biotech volatility and trial uncertainties.

• Risks and Opportunities: High risk due to late-stage trial outcomes, regulatory hurdles, and funding needs. Upside includes strong commercial launch post-approval and better-than-expected clinical results. Downside risks include competition in neuromuscular drugs and potential trial failures.

• Catalysts: Encouraging data from the FORTITUDE biomarker cohort in Q2 2026, phase 3 results, and company strategy discussions as it transitions to commercial stage.